March 24, 2017 08:43 AM EDT
Financing

That $95M Mer­ck gam­ble to ac­quire cCAM? It didn’t pay off.

John Carroll

Editor & Founder

When Mer­ck $MRK ac­quired cCAM Bio­ther­a­peu­tics in Is­rael in the sum­mer of 2015, R&D chief Roger Perl­mut­ter and his crew were in­trigued by the po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times